Signed in
We value your privacy
This site uses cookies to improve your browsing experience, analyze site traffic, and show personalized content.
Welcome to Pump.fun!
Pump lets anyone create coins, giving everyone equal access to buy and sell from the start. Prices can move quickly, so trade carefully.
By clicking this button, you agree to the Terms and Conditions, Privacy Policy, and certify that you are over 18 years old.
We value your privacy
This site uses cookies to improve your browsing experience, analyze site traffic, and show personalized content.
Stats
0.00%
Supply change
0.00 SOL
Liquidity
—
Mayhem trades
-0 SOL
Mayhem Agent Profit
Actions
Mayhem agent completed
Mayhem mode has ended, either the 24-hour window expired or the SOL reserves were depleted.
Paired with SOL| No holders yet. | ||||||||||
Did They Just Cure Cancer? Summary • Merck and Moderna reported positive Phase 3 results for intismeran autogene, an individualized mRNA cancer vaccine. • The result marked the first positive Phase 3 readout for a personalized neoantigen therapy. Read the full story Merck and Moderna reported positive Phase 3 results for intismeran, their personalized cancer vaccine, when used with KEYTRUDA in melanoma patients who had undergone surgery. Intismeran is personalized using mutations found in each patient’s tumor. Researchers analyze the tumor, then create an mRNA treatment designed to target up to 34 tumor specific markers. In the Phase 3 trial, Intismeran combined with KEYTRUDA significantly improved how long patients remained cancer free and reduced the risk of cancer spreading compared with KEYTRUDA alone. The trial met its main goals early, marking the first positive Phase 3 result for an individualized mRNA cancer therapy. Professor Georgina Long, the trial’s principal investigator, called the results a “landmark moment for adjuvant melanoma treatment.” Moderna stock, MRNA surged over +100% following the trial results. The Kobeissi Letter highlighted the move in a post about the announcement.